MTM Laboratories Adds $9.7 Million To Series C Round

Diagnostics company MTM Laboratories has expanded its Series C round, raising an additional 7 million Euro and bringing the total raised to 46 million Euro ($63 million). Heidelberg-based MTM Laboratories will use the additional financing for clinical trials and commercialization of its technology, which is designed for early detection and diagnosis of cervical cancer. The Series C financing was led by HBM BioVentures, Wellington Partners and Gilde Healthcare Partners; and included investment from National Technology Enterprises Company, Heidelberg Innovation and private investors.

North AmericaUSBriefs